Table 1 |
|||
|
Incidence of pleural effusion in patients with CP CML with exposure to dasatinib |
|||
|
Dosage |
|||
|
|
|||
|
70 mg twice daily n = 167 |
100 mg once daily n = 166 |
P-value |
|
|
|
|||
|
Pleural effusiona |
|||
|
All grades |
26 (16%) |
12 (7%) |
0.024 |
|
Grades 3-4 |
2 (1%) |
2 (1%) |
- |
|
|
|||
|
aClassifications are as follows: grade 1, asymptomatic; grade 2, symptomatic, intervention with diuretics or up to two therapeutic thoracenteses indicated; grade 3, symptomatic and supplemental oxygen is required, greater than two therapeutic thoracenteses, tube drainage, or pleurodesis indicated; grade 4, life-threatening (e.g., causing hemodynamic instability); grade 5, death. Data from Shah et al[22] |
|||
|
Masiello et al. Journal of Hematology & Oncology 2009 2:46 doi:10.1186/1756-8722-2-46 |
|||
